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Abstract
As an arthropod-borne human pathogen, Rift Valley fever virus (RVFV) cycles between an insect vector and mammalian
hosts. Little is known about the cellular requirements for infection in either host. Here we developed a tissue culture model
for RVFV infection of human and insect cells that is amenable to high-throughput screening. Using this approach we
screened a library of 1280 small molecules with pharmacologically defined activities and identified 59 drugs that inhibited
RVFV infection with 15 inhibiting RVFV replication in both human and insect cells. Amongst the 15 inhibitors that blocked
infection in both hosts was a subset that inhibits protein kinase C. Further studies found that infection is dependent upon
the novel protein kinase C isozyme epsilon (PKCe) in both human and insect cells as well as in adult flies. Altogether, these
data show that inhibition of cellular factors required for early steps in the infection cycle including PKCe can block RVFV
infection, and may represent a starting point for the development of anti-RVFV therapeutics.
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Introduction
Viral pathogens are a common cause of morbidity and mortality
in the developing and developed world. Of particular concern are
emerging and re-emerging epidemic arboviral diseases that are
spread by mosquitoes and other biting insects [1]. Most
arboviruses impacting public health fall into one of three viral
families: Flaviviridae, Togaviridae, and Bunyaviridae. Bunyavi-
ruses are enveloped, negative-sense tripartite RNA viruses that
include Sin Nombre, Hantavirus, Crimean-Congo hemorrhagic
fever virus and Rift Valley fever virus (RVFV). RVFV is an
important emerging pathogen due to its frequent outbreaks [2].
While humans infected with RVFV typically have a self-limited
febrile illness, 1-3% die as a result of hemorrhagic symptoms [3].
RVFV was initially only endemic in sub-Saharan Africa, although
the regions affected by the virus have expanded and now include
Egypt and the Arabian Peninsula. In addition to Aedes sp., a broad
range of mosquito species has been linked to the spread of RVFV,
increasing the chances that RVFV may spread to other countries
[4,5].
RVFV, and arboviruses in general, are remarkable because they
have not only developed highly effective strategies to hijack
cellular machinery and to subvert hosts’ immune responses, but
they have evolved these capabilities in broad host ranges, spanning
arthropods and mammals. While infection of the insect host has
little pathogenicity, infection of mammals is associated with
disease. Little is known about the host factors required for the
replication cycles of these viruses in either of their host genera,
which impedes development of antiviral treatments.
Classically, antivirals have been developed as a result of high-
throughput screens (HTS) that target specific viral enzymes. This
target-based approach fails to investigate other possible targets
including essential cellular factors that enable infection, or viral
proteins with unknown function. Targeting cellular factors may be
advantageous because such treatments are less liable to be evaded
by the high mutation rate of viral genomes. In addition, the use of
Drosophila as a model insect makes it possible to take advantage of
the powerful genetic tools available in this organism to both screen
and to test the role of identified targets at the organismal level
[6,7,8,9,10,11,12,13,14].
We developed a cell- and image-based high-throughput
screening platform that allowed us to screen a library of 1280
known biologically active small molecules for inhibitors of RVFV
(strain MP12) infection in both human and Drosophila cells [15].
Using this strategy we identified a number of inhibitors that
suppressed infection in cell lines derived from both hosts. Amongst
the over-represented classes of inhibitors were drugs that are
known to target macropinocytosis, including phosphatidylinositol
3-kinase (PI3K) and protein kinase C (PKC) inhibitors. Macro-
pinocytosis is a receptor-independent endocytic mechanism that is
a known entry route for some viruses, although this mechanism
has not been shown to control the entry of RVFV, other
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Further studies focused on that the role of PKC in infection. We
found that the classical PKC isozymes were dispensable for
infection while the novel PKC isozyme, PKC epsilon (PKCe),
promotes RVFV MP12 infection. Inhibition of PKCe in human
cells, Drosophila cells or adult flies significantly attenuated infection
Together, these data show that RVFV MP12 infection of both the
insect and mammalian host has conserved cellular requirements
that are amenable to therapeutic intervention.
Results
RVFV MP12 infection of Drosophila and mammalian cells
To identify cellular factors that impact viral replication in
mammalian and insect cells we used an attenuated strain of RVFV,
MP12 [20]. This strain differs by 11 amino acids from the wild type
strain ZH548, making it likely that cellular factors required for
MP12 replication will also be needed for wild type strains [21]. We
generatedhigh-titervirusinVerocells(10
7 pfu/mL)andusedthisto
infect mammalian cells including Vero, HeLa and 293T, and insect
cells including mosquito C6/36 and Drosophila S2 cells. We found
that the RVFV strainMP12infected all cell lines tested as measured
by an immunofluorescence assay in which newly produced viral GC
glycoproteins were detected after infection (data not shown). In
Vero and Drosophila S2cells,the viralglycoproteinsco-localizedwith
a Golgi apparatus marker as previously described (Figure 1A, B)
[22,23]. Importantly, RVFV MP12 infection of human and
Drosophila cells was productive, leading to the generation and
release into the media of infectious progeny (Figure 1C, D) and
spread of virus in both human and insect cell cultures (data not
shown), demonstrating that we can use both mammalian and
Drosophila cells to study the entire replication cycle of RVFV.
To quantify infection, we stained cells with an antibody to a viral
antigen (GC) and counterstained with DAPI to observe cell nuclei.
Automated imaging was used to capture three sites per well in a 96
well plate, and images were analyzed using MetaXpress software to
measure percent infection (Gc
+/DAPI
+). We used a similar assay to
monitor infection of insect cells, though infection times were longer
due to slower virus replication, possibly caused by the lower
temperature. Using this assay, we found that in mammalian 293T
cells the lysosomotropic agent Ammonium Chloride inhibited
infection by 12-fold (Figure 1E). Likewise, in Drosophila cells, RVFV
MP12 replication was also dependent on intracellular acidification at
a similar concentration (Figure 1F). This confirms that viral infection
is dependent upon an acidified cellular compartment in insect and
mammalian cellsand showsthat we can use small molecule inhibitors
to probe the biology of infection in a quantitative manner.
Screen for inhibitors of RVFV infection
To screen drugs for the ability to inhibit RVFV MP12, we
developed an assay for RVFV infection of both human and
Drosophila cells in a 384-well format. We optimized cell number for
384-well plates, viral innoculum, and staining parameters. We
tested for tolerance to DMSO (,1% tolerated in both cell lines) and
temperature (293T cells are robust for up to 4 hours at room
temperature). To assess the extent of infection, we captured 3 sites
per well for 3 wavelengths (nuclei and the viral structural proteins N
andGN).Theseimageswereanalyzed usingMetaXpresssoftwareto
capture the number of cells and the number of infected cells
(number N
+ and GN
+). Robust statistics were used to generate the
metrics used to identify outliers or potential candidate modulators.
We calculated the percent infection for each well, log transformed
the data, calculated the median and interquartile range from which
we calculated a robust Z score plate-by-plate [24].
Next, we used this assay platform to screen for small molecule
inhibitors of RVFV MP12 infection both in human (293T) and
Drosophila (S2) cells (Schematic Figure 2A). We screened a
commercially available library of 1280 compounds (Sigma
LOPAC
1280) that contains marketed drugs and relevant structures
with predictable activities and proven scaffolds directed against a
wide range of known drug targets including GPCRs and protein
Figure 1. RVFV MP12 productively infects both human and
Drosophila cells. A. Vero cells were infected at an MOI=0.08 for
15 hours and RVFV infection was detected by immunofluorescence
using mouse anti-RVFV Gc (red), anti-TGN46 (Golgi marker, green), and
the nuclear dye DAPI (blue). Inset shown at higher magnification. B.
Drosophila S2 cells were infected at an MOI=0.02 for 48 hours and
RVFV infection was detected by indirect immunofluorescence using
mouse anti-RVFV GN (red), anti-GM130 (Golgi marker, green), and the
nuclear dye DAPI (blue). Inset shown at higher magnification. C–D.
RVFV MP12 produced in Vero cells (C)o rDrosophila S2 cells (D) was
used to infect 293T/17 cells and detected by immunofluorescence with
mouse monoclonal anti-RVFV N (green) and the nuclear dye DAPI
(blue). E–F.A m m o n i u mC h l o r i d e( N H 4Cl; 960 mM) inhibits RVFV
infection in mammalian 293T cells infected at an MOI of 0.1 for
15 hours (E) and Drosophila S2 cells (F) infected at an MOI of 0.1 for
48 hours. Infected cells were visualized by immunofluorescence against
RVFV N (green) and counterstained with DAPI (blue).
doi:10.1371/journal.pone.0015483.g001
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0.25% DMSO. The robust Z scores for the percent infection are
plotted for all 1280 compounds with the replicates on each axis for
human cells (Figure 2B) and Drosophila cells (Figure 2C). Drugs
with a Z score of ,21.7 in duplicate represent our positive
candidates for this screen (p,0.002) and are in the lower left
quadrants of Figure 2B–C.
Analysis of nuclei presents a simple counter-screen for
cytotoxicity
An important facet of drug screening is the development of
counter-screens that allow the identification and removal of
artifactual sources of activity, such as compounds that suppress
virus infection via cytotoxic effects or by general inhibition of
cellular metabolism. Using the information on cell number
obtained in this high-content format, we applied the same robust
statistics to cell counts, making it possible to identify cytotoxic
small molecules in each well (Figure S1). Using this simple strategy,
we stratified the candidates into toxic versus non-toxic inhibitors.
Drugs were considered toxic if the Z score was less than 22i n
duplicate at 10 mM( .20% decrease in cell number). Of the 46
drugs that inhibited infection in 293T cells, 24 showed toxicity
while 19 of the 28 drugs identified in Drosophila cells were cytotoxic
at 10 mM (Table S1). While a significant number of our candidates
were toxic at 10 mM, we were able to uncouple viral inhibition
from cytotoxicity for a number of inhibitors simply by decreasing
Figure 2. High-throughput screen for inhibitors of RVFV infection. A. Schematic of screening strategy used in human and insect cells. Cells
are seeded in 384 well plates, subsequently 10mM drug was added. The cells were infected with RVFV, then fixed, stained and imaged using
automated microscopy. Automated image analysis and statistical thresholds were used to identify inhibitors of RVFV infection. Candidate drugs are
then validated and further characterized. B. 6,000 293T cells were plated in 384 well plates, treated with inhibitor and infected at MOI=0.06 for
16 hours. Robust Z scores for infection in mammalian were plotted for each replicate in blue. Each of the four plates is denoted by a different symbol.
C. 20,000 S2 cells were plated in 384 well plates, treated with inhibitor and infected at MOI=0.02 for 48 hours. Robust Z scores for infection in
mammalian were plotted for each replicate in red. Each of the four plates is denoted by a different symbol. D. Annotated categories of 59 candidate
RVFV inhibitors from LOPAC screen. * denotes over-represented groups p,0.02. E. Venn diagram of the distribution of small molecules: 31
mammalian (blue), 13 insect (red) and 15 pan-inhibitors (purple). * p,10
216. F. Categories of 15 candidates that block infection of both mammalian
and Drosophila cells. * denotes over-represented groups p,0.02.
doi:10.1371/journal.pone.0015483.g002
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target specificity (see below and Table 1).
Candidate inhibitors of RVFV infection
Using this approach we identified 46 drugs that attenuated
infection in 293T cells while 28 drugs did so in S2 cells. The larger
number of drugs identified in human cells likely reflects the fact
that these small molecules were developed for use in mammalian
systems. Analysis of the categories of all of the drugs identified
revealed 23 classes, as determined by the LOPAC library (Table
S1, Figure 2D). Drugs inhibiting ion pumps and the cytoskeleton
were significantly overrepresented in the results compared to the
representation in the library (p,0.02).
Strikingly, there was a large overlap in the drugs identified that
attenuate infection in both cell types, indicating pathways utilized
by the virus in both mammals and insects (p,10
216; Figure 2E).
Analysis of the inhibitors that attenuated infection in both cell
types revealed that the inhibitors could be divided into 9 specific
categories. Drugs inhibiting PKC, ion pumps, the cytoskeleton and
apoptosis inducers were all significantly overrepresented in the
data set compared to the library (P,0.02; Figure 2F).
Furthermore, a subset of these drugs are known inhibitors of
macropinocytosis, a well-established entry pathway for a variety of
viruses [16,17,18,19]. Macropinocytosis is dependent upon PI3K
activity, sodium/hydrogen antiporters, as well as an intact
cytoskeletal network. It is also dependent upon PKC activity,
though the specific PKC isoform(s) important for this process are
not known. We identified inhibitors against each of these targets
including Wortmannin, a well-known PI3K inhibitor, Rottlerin
and Chelerythrine Chloride which are broadly-active PKC
inhibitors, and antiporter inhibitors including amiloride deriva-
tives such as EIPA [25]. Although some of the drugs that target
PKC or macropinocytosis inhibited infection in only one cell type,
we identified some inhibitors that reduced infection in both cell
types (Table S1). We were particularly interested in validating
those compounds that reduced RVFV MP12 infection in both
hosts as they likely target fundamental aspects of RVFV
replication.
Validation of RVFV inhibitors
To validate our candidates, we re-tested a subset in both
mammalian and insect cells (Figure 3, Table 1). We concentrated
Table 1. Inhibitors of RVFV infection.
Drug Name Drug Class Cell type in screen
IC50 (mM)
293T
Toxicity
uncoupled 293? IC50 (mM) S2
Toxicity
uncoupled S2?
EIPA Ion Pump Both 20.6 yes 17.6 not toxic
Chelerythrin Cl PKC Both ** no 6.6 yes
Rottlerin PKC Both 2 yes 4.3 yes
Thioridazine Ca
2+ Channel Both 26.2 yes 24.4 not toxic
Thapsigargin Intracellular Calcium Both 0.6 yes 0.2 yes
Mibefradil Ca
2+ Channel 293T 12.4 yes 8.1 not toxic
Brefeldin A ER/Golgi transport 293T 0.7 yes 1 not toxic
DEQ K
+ Channel S2 44.3 not toxic 1.4 not toxic
PMA PKC 293T NO not toxic NO not toxic
Methotrexate DNA Metabolism 293T ** no 94.4 yes
Sanguinarine Cl Ion pump 293T 4.8 yes 2.9 yes
Tyrphostin A9 CRAC chanel 293T 2.5 yes 1.1 yes
Spiperone Ca
2+ Channel 293T 45.9 not toxic 49.7 not toxic
Wortmanin PI3K S2 0.2 yes 0.6 yes
U73122 Lipid S2 ** no 1.4 yes
DMA Ion Pump 293T 52.2 not toxic 15 not toxic
Vinblastine Sulfate Microtubules Both 24.7 yes 0.3 yes
Drugs used that were not in the screen
Ribavirin Nucleoside analog 41.9 10
Chloroquine Acidification 41.2 31.9
Ammonium Cl Acidification 310.3 98.5
CytocholasinD Actin ** 0.2
Nocodozole Microtubules 35.9 47.7
PKC inhibitors:
GF109203X pan-PKC ** NO
Calphostin C pan-PKC 1.4 8.9
Go ¨6976 Classical PKC NO 49.3
PKC Inhib 20–28 Classical PKC NO NO
Ro-332-0432 Classical PKC NO NO
doi:10.1371/journal.pone.0015483.t001
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types as well as the over-represented categories of ion pumps
(EIPA), PI3K (Wortmannin), PKC inhibitors (Rottlerin, Cheler-
ythrin Chloride), and calcium inhibitors (Thioridazine, Thapsi-
gargin), many of which are known in mammalian cells to inhibit
macropinocytosis. Cytoskeletal inhibitors were also over-repre-
sented in our set and included 3 of the 5 microtubule inhibitors in
the set and Brefeldin A, an inhibitor of secretion. Inhibitors of the
actin cytoskeleton were absent from the library. Altogether, we re-
tested 17 candidates listed in Table 1 and found that all but one
attenuated infection in one or both cell types, making our false
positive rate quite low. Furthermore, we found that all inhibitors
efficacious in 293T cells inhibited RVFV MP12 infection in the
HeLa and Vero cells (data not shown). We also tested the actin
inhibitor Cytochalasin D and control drugs including Ribavirin,
Chloroquine and Ammonium Chloride (Table 1), and these too
inhibited infection.
IC50 values were calculated for inhibitors both in insect and
human cells (examples in Figure 3, Table 1). In doing this, we
could uncouple cytotoxicity and viral inhibition for a number of
drugs, using robust statistical calculations on nuclei as described
for the screen to determine cytotoxicity. All six drugs that were
Figure 3. Validation of RVFV candidate inhibitors. A. 293T cells were pre-treated with 7 mM Rottlerin, 160 mM EIPA, 16 mM Mibefradil, or
vehicle, and infected with RVFV MP12 (MOI=0.3) for 16 hours and monitored by immunofluorescence with anti-RVFV N (green) and the nuclear dye
DAPI (blue). Infected cells were visualized by immunofluorescence and the percent infection quantified as above. B. Drosophila S2 cells were pre-
treated with 21 mM Rottlerin, 53 mM EIPA, 48 mM Mibefradil, or vehicle, and infected with RVFV MP12 (MOI=0.05) for 48 hours and monitored by
immunofluorescence with anti-RVFV N (green) and the nuclear dye DAPI (blue). Infected cells were visualized by immunofluorescence and the
percent infection quantified as above. C.I C 50 concentrations for the indicated drugs were determined for mammalian 293T cells and Drosophila S2
cells.
doi:10.1371/journal.pone.0015483.g003
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at concentrations that were no longer toxic (Table 1). Nine of the
11 drugs that were cytotoxic in the primary 293T screen were no
longer toxic at concentrations that remained inhibitory to infection
(Table 1). This is due to the fact that in many cases, toxicity is due
to off-target effects that may be affecting another essential protein
at a higher concentration than the previously described target. We
calculated IC50 values only for non-toxic compounds (Table 1).
However, some of the drugs remained highly cytotoxic in
mammalian cells, significantly reducing the number of cells at all
concentrations that were inhibitory to RVFV MP12 infection;
thus, IC50 values were not calculated for those drugs (denoted by
**, Table 1). Importantly, the drugs that did attenuate both cell
types did so with similar IC50 values suggesting that they are
targeting the same cellular factor. These studies showed that our
small molecule screen identified a number of anti-RVFV MP12
compounds including multiple inhibitors previously shown to
block macropinocytosis.
Some inhibitors block an early step of RVFV infection
The lifecycle of RVFV, like that of any virus, involves sequential
steps that can be kinetically dissected. Performing time-of-addition
experiments can determine if an inhibitor blocks early versus late
steps in the lifecycle. We found that binding and entry of RVFV
MP12 takes approximately one hour in 293T cells because
treatment with lysosomotropic agents such as Ammonium
Chloride one hour post-infection no longer blocked infection
(Figure 4). In contrast, we found that the nucleoside analog
Ribavirin, which inhibits RNA replication, remained inhibitory
when added one hour post-infection (Figure 4). Therefore, by
treating cells with inhibitors at one hour post-infection, we could
determine whether the small molecules targeted an entry or post-
entry step in the RVFV MP12 lifecycle.
For these time-of-addition experiments, we tested inhibitors
identified in the screen, including two known inhibitors of
macropinocytosis, the Na
+/H
+ antiporter EIPA and the PKC
inhibitor Rottlerin and the microtubule inhibitor Vinblastine.
Using this assay we found that all three drugs suppressed RVFV
MP12 infection if present at the time of virus addition, but were
unable to efficiently inhibit replication when added post-entry
(Figure 4). In contrast, the control compound Ribavirin remained
inhibitory when added post-entry.
Protein Kinase C epsilon promotes RVFV infection of
mammalian cells
While PKC activity is required for efficient RVFV MP12
infection, it is unclear which gene or isozyme is important for this
process. The protein kinase C family comprises 3 classes: cPKC
(classical), nPKC (novel), and aPKC (atypical), based on their
overall structural similarity and sensitivity to inhibitors [26]. The
activity of cPKC isozymes is stimulated by diacylglycerol, calcium,
and phosphatidylserine, that of novel isozymes by diacylglycerol
and phosphatidylserine, and that of aPKC’s by phosphatidylserine.
To determine which PKC isozyme class was required for RVFV
Figure 4. Time-of-Addition Assays. A. 293T/17 cells were either pre-treated with the indicated drugs or treated with drugs 1 hour post infection
(MOI=0.3) for 12–15 hours. Representative images from cells treated with NH4Cl, Ribavirin, EIPA, Rottlerin and Vinblastine are shown. Cells stained
with FITC anti-RVFV N (green) and counterstained with DAPI (blue). B. Quantification of the time of addition assay in A. was graphed to show the
normalized percent infection for the indicated drugs tested. Blue bars are the pre-treatment, and red bars are the one hour post infection treatments.
doi:10.1371/journal.pone.0015483.g004
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activated calcium signaling. If calcium signaling were activated, it
would suggest that a calcium-dependent PKC isozyme might be
required. To assay for calcium we used a reporter system that
drives the expression of luciferase from the Cre or NFAT
promoters in stably or transiently transfected 293T mammalian
cells, which are activated by calcium signaling. RVFV MP12
infection did not impact signaling from these promoters (data not
shown) [27,28], making it less likely that the classical PKC
isozymes play a central role in the cellular entry of RVFV MP12.
We then tested additional PKC inhibitors that either inhibit all
PKC isozymes (Calphostin C) or only the classical PKCs (Go ¨6976,
PKC Inhib 20–28, Ro-332-0432) as characterized in mammalian
cells. We found that the pan-PKC inhibitor Calphostin C
inhibited infection in both cell types similar to Rottlerin and
Chelerythrine Chloride (Table 1). In contrast, Go ¨6976, PKC
Inhib 20–28, or Ro-332-0432 were unable to inhibit RVFV MP12
infection in mammalian cells, while Go ¨6976 had a weak inhibitory
effect in Drosophila cells, a cell type that has not been characterized
for sensitivity to these inhibitors (Table 1) [29]. These data suggest
that the classical PKC isozymes were not essential for RVFV
MP12 infection, but that the novel PKC isozymes may promote
viral infection.
Because small molecules may inhibit more than one protein,
thus having off target effects, we wanted to validate the inhibitor
results using an independent approach. To this end, we used RNA
interference technology to specifically deplete each of the two
major nPKC isozymes, PKCdelta (PKCd) and PKCepsilon
(PKCe). We transiently transfected 293T cells with either a
control non-targeting siRNA or a siRNA against PKCd or PKCe,
waited three days for depletion, and challenged the cells with
RVFV MP12 for 12 hours. Under these conditions we consistently
observed an approximately two-fold decrease in the percentage of
infected cells that were depleted for PKCe compared to both the
controls and PKCd-depleted cells at two different MOIs
(Figure 5A). Immunoblot analyses demonstrated that the siRNA
against PKCe significantly depleted, but did not eliminate, PKCe
protein levels compared to untreated or non-targeting controls
(Figure 5B).
As an alternative approach to investigate the contribution of
PKCe to RVFV MP12 infection, we generated stable hairpin-
expressing human adenocarcinoma H358 cell lines that express
either a control hairpin or a hairpin against PKCe.W e
determined the infectivity of these cells by plaque assay and found
that there was a significant decrease in plaque number in the
PKCe-depleted cells (Figure 5C). Again, we found that PKCe was
depleted in the PKCe hairpin-expressing cells compared to either
untreated cells or the control hairpin-expressing H358 cells
(Figure 5D). To determine whether PKCe is specifically required
for RVFV MP12 infection, or generally required for all viruses, we
tested whether poliovirus infection was sensitive to depletion of this
factor. Poliovirus, a prototypical picornavirus, is a non-enveloped,
positive-stranded RNA virus. Poliovirus infection was not
impacted by siRNA against PKCe (Figure 5E) nor by the PKCe
hairpin in H358 cells (Figure 5F). These data show that
suppression of PKCe levels specifically reduces RVFV MP12
infection of mammalian cells although to a lesser extent than the
small molecule inhibitors.
Protein Kinase C epsilon is required for efficient RVFV
infection of an insect
To study this further at the organismal level, we tested whether
RVFV MP12 could successfully infect and replicate in adult flies.
As is the case for RVFV infection of their natural mosquito host,
infection of Drosophila by direct injection of either 16.5 PFU or 165
PFU of RVFV MP12 into the abdominal cavity was non-lethal
(Figure 6A). We next tested whether the virus was replicating in
the animal. By three days post infection we could detect the
production of the viral GN and GC glycoproteins by immunoblot,
the levels of which increased as a function of time post infection
(Figure 6B). This shows that RVFV MP12 can infect and replicate
in flies.
To test the potential role of PKC in infection of an organism, we
used the Gal4/UAS system to express a pseudo-substrate inhibitor
of PKC (PKCi), which has been previously shown to competitively
inhibit different PKC isoforms in adult flies [30]. This peptide
inhibits all PKC activity in the fly with an IC50 of 0.4 mM. We
crossed transgenic flies that can express this specific peptide
inhibitor of PKC (PKCi) to transgenic flies that express Gal4
ubiquitously and at high levels downstream of the actin 5C
promoter. Over-expression of this transgene does not lead to
lethality or a defect in lifespan (data not shown). We challenged
flies expressing the PKC inhibitor or sibling controls and
monitored the levels of RVFV MP12 replication both by
immunoblot and plaque assay analyses post-infection. We found
that there was a significant decrease in viral protein production in
the PKC inhibited flies (Figure 6C). Furthermore, viral titers were
significantly decreased in the PKC inhibited flies (Figure 6D). As a
control, we infected flies with Drosophila C virus, a picorna-like
virus and a natural pathogen of Drosophila [15]. We monitored the
levels of Drosophila C virus antigen production by immunoblot as
a function of time post-infection and found that there was no
change in viral replication in the PKC inhibited flies (Figure 6E).
Altogether, these findings are consistent with the PKC inhibitor
data that Chelerythrine Chloride, Calphostin C, and Rottlerin
inhibit RVFV MP12 infection of Drosophila cells (Table 1).
Drosophila has homologs for many of the mammalian PKC
isozymes including epsilon. Therefore, we next tested whether the
Drosophila PKCe homolog, PKC98e, was also required in Drosophila
for RVFV MP12 replication as we demonstrated in human cells.
Unlike many of the other PKC isozymes in flies, but similar to
mammals, PKCe is expressed ubiquitously and at high levels in the
adult (http://flyatlas.org/atlas.cgi?name=FBgn0003093) [31].
We tested a requirement for PKCe through the use of a transgenic
strain of flies expressing an inverted repeat or snap-back construct
against PKCe. Upon expression of this transgene, a double-
stranded RNA is produced which is complementary to PKCe
mRNA, and results in RNA interference and depletion of PKCe.
Using the Gal4/UAS two-component system we induced
expression in adult flies using transgenic animals that express
Gal4 under a heat shock promoter. We verified that PKCe was
indeed depleted by RT-PCR (Figure S2). Next, PKCe-depleted
flies or controls were challenged with RVFV MP12 and monitored
again for viral replication. We found that PKCe-depleted flies
supported a decreased level of RVFV MP12 replication as
measured by viral antigen production (Figure 6F). In addition,
viral titers were significantly decreased in PKCe-depleted flies
(Figure 6G). In contrast, we found that PKCe-depleted flies
supported a similar level of Drosophila C virus replication as
measured by viral antigen production (Figure 6H). These data
demonstrate that PKCe is specifically required for RVFV MP12
infection in adult flies.
Discussion
Arboviruses constitute a group of relatively understudied viruses
for which there are no therapeutics or vaccines. RVFV, a member
of the Bunyaviridae family, not only causes significant morbitity and
PKCe Promotes Rift Valley Fever Virus Infection
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bioterrorism agent due to presence of permissive vectors in the
United States. Little is known about the cellular pathways and
factors co-opted for the replication cycle of RVFV in either the
insect or mammalian host. However, the fact that RVFV replicates
efficiently in such diverse hosts suggests that it may utilize conserved
hostfactorsandpathwaysaspartofitsreplicationcycle.Tothisend,
we first developed a high-throughput assay to monitor infection of
the attenuated strain MP12 in both insect cells (Drosophila S2 cells)
andhumancells(293T cells)andused thisassayto probea library of
small molecules with known or predicted targets. Using this strategy
we set out to uncover essential pathways and gene products
subverted by RVFV MP12 for infection. Moreover, by performing
this screen in parallel with host cells derived from insects and
humans we could readily assess the similarities and differences
between the host factor dependencies.
Figure 5. PKCepsilon is required for RVFV infection of human cells. A. Human 293T cells were transfected with siRNAs against a control, or
the novel PKC isozymes PKCd or PKCe. The depleted cells were challenged with RVFV MP12 (MOI=1) for 12 hours were processed for
immunofluoresecnce and quantified. Mean6sd for three experiments; * p,0.02. B. PKCe is depleted by siRNA treatment as measured by immunoblot
compared to a non-specific control (NS). C. Human H358 cells stably expressing either a control hairpin or a PKCe specific hairpin were challenged
with RVFV MP12 for plaque assays in duplicate for each experiment, averaged, and the fold-change compared to control of the pfu/mL was averaged
across three independent experiments; * p,0.02. D. PKCe was depleted by RNAi as measured by immunoblot compared to a tubulin control. E.
Human 293T cells were transfected with siRNAs against a control, or the PKCe and the depleted cells were challenged with poliovirus for 8 hours,
processed for immunofluorescence and quantified. Mean6sd for three experiments. F. Human H358 cells stably expressing either a control hairpin or
a PKCe specific hairpin were challenged with poliovirus for 8 hours, processed for immunofluorescence and quantified. Mean6sd for three
experiments.
doi:10.1371/journal.pone.0015483.g005
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cologically active small molecules that suppressed RVFV MP12
infection in insect and mammalian cells, with many of these
targeting molecules involved in signaling pathways. A larger
number of compounds suppressed RVFV MP12 exclusively in
mammalian cells, but whether this indicates significant differences
in how RVFV interacts with mammalian and insect cells or
whether the compounds (identified via their abilities to inhibit
mammalian targets) fail to interact with their Drosophila homologs
is not yet known.
Among the inhibitors of RVFV MP12 infection identified in
both hosts were several that target PKC. PKC is a family of closely
related serine/threonine kinases that regulate diverse processes,
with several having been implicated as playing roles in virus
infection, dissemination or pathogenesis [32,33,34,35]. There are
three classes of PKC isozymes that have distinct cofactor
Figure 6. PKCe is required for RVFV infection in adult flies. A. RVFV MP12 infection of adult flies is non-lethal. Wild type flies (w1118) were
infected with either 165pfu or 16.5pfu or vehicle control (PBS) and monitored daily for lethality. A representative experiment is shown of three
independent experiments. B. RVFV infection of adult flies can be monitored by an increase in viral antigen production as a function of both dosage
and time. Wild type flies were inoculated with the indicated pfu/fly and processed for immunoblot for the glycoproteins GN and GC at the indicated
days post infection. A representative experiment is shown of two independent experiments. C. Adult flies over-expressing the PKC inhibitor (Actin-
Gal4.UAS PKCi) have decreased levels of viral glycoprotein production as measured by immunoblot as compared to sibling controls that do not
express the inhibitors (+.UAS PKCi). There are decreased levels of both monomers and dimers (*). A representative experiment is shown of three
independent experiments. D. Adult flies over-expressing the PKC inhibitor generated and infected as in C. have decreased viral progeny production
day 4 post infection compared to controls as measured by plaque assay on Vero cells. Replicate experiments are shown. E. Adult flies over-expressing
the PKC inhibitor (Actin-Gal4.UAS PKCi) have no change in the levels of Drosophila C virus infection as measured by immunoblot against the capsid
proteins normalized to control. F. Adult flies depleted for the PKC epsilon isozyme (Heat Shock-Gal4.UAS-PKCe IR) have decreased levels of viral
glycoprotein production as measured by immunoblot as compared to controls that are not depleted for PKCe (Heat Shock-Gal4.+). There are
decreased levels of both monomers and dimers (*). A representative experiment is shown of three independent experiments. G. Adult flies depleted
for PKCe generated and infected as in F. have decreased viral progeny production day 4 post infection compared to controls as measured by plaque
assay on Vero cells. Replicate experiments are shown. H. Adult flies depleted for the PKC epsilon isozyme (Heat Shock-Gal4.UAS-PKCe IR) have no
change in the levels of Drosophila C virus infection as measured by immunoblot compared to controls that are not depleted for PKCe (Heat Shock-
Gal4.+).
doi:10.1371/journal.pone.0015483.g006
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family member was involved in RVFV MP12 infection. Using
more specific pharmacological inhibitors we found that the
classical PKC isozymes were dispensable, but a novel PKC
isozyme was important for infection. The novel PKC isozymes are
calcium insensitive, but phospholipid and diacylglycerol-depen-
dent. Although the activation mechanisms between these classes
are distinct, the specific function of each isozyme has been difficult
to establish because in many cases these kinases have overlapping
substrate specificities. Moreover, studies from dominant-negative
or constitutively active isozymes have been misleading, necessitat-
ing loss-of-function studies. We used RNA interference both in
human cell lines and adult fruit flies to demonstrate a specific role
for PKCe in promoting RVFV MP12 infection. While the PKC
inhibitors routinely inhibited infection by at least 10-fold, RNAi
modestly but significantly attenuated infection (,2-fold). There
are a number of possible explanations. First, our knock down was
only partial, while the small molecules are more potent. A stronger
depletion might reveal a stronger dependence on PKCe.
Alternatively, multiple isozymes may contribute to the phenotype,
making a single knock-down weaker. Lastly, it is possible that the
drugs may be targeting multiple genes that are playing roles in
viral infection. While possible, we feel it is unlikely since a number
of structurally unrelated inhibitors that target PKC are inhibitory
to RVFV replication. The likelihood that the alternate targets of
each of these inhibitors are the same is low.
Time-of-addition experiments indicated that PKC activity
promoted infection at the time of viral entry, suggesting that
intracellular signaling through PKC was facilitating this process.
PKC inhibitors have also been shown to block infection with West
Nile virus, an arbovirus in the Flaviviridae family [35]. In the case of
RVFV entry, infection is dependent on its delivery to an acidic
cellular compartment as low pH provides the trigger for the
conformational changes needed for membrane fusion. However,
the precise route taken by RVFV to reach an acidic compartment is
not known. Most small, enveloped viruses have been shown to enter
cells by either clathrin-mediated or caveolin-mediated endocytosis
[16]. Although there has been little work on bunyavirus entry
pathways to date, recent studies have revealed that a number of
different hantaviruses, a class of bunyaviruses, are dependent upon
actin and microtubule networks for entry, as we have shown for
RVFV MP12 [36]. PKCe contains an actin binding motif that is
unique to this individual member of the PKC family [37] suggesting
that this isozyme may be playing a role in this context.
Furthermore, we identified a number of the classic inhibitors
used to block macropinocytosis as required for efficient RVFV
MP12 infection. Early ultrastructural studies of RVFV infection of
Vero cells revealed that virus is taken up in large protrusions,
consistent with macropinosomes [38]. Adenovirus, a small DNA
virus, utilizes both macropinocytosis and clathrin-mediated
endocytosis for infection, triggered by receptor engagement [39].
The virus itself is internalized in clathrin-coated pits, but is unable
to enter cells without concomitant activation of macropinocytosis,
which facilitates the pH-activated escape from endosomes. In
contrast, vaccinia, a large DNA virus, both triggers macropino-
cytosis and is dependent upon this pathway for entry [19]. Further
studies are necessary to determine if there is a role for
macropinocytosis in RVFV entry and infection.
We found that when macropinocytosis inhibitors were used or
when PKCe expression was suppressed, RVFV MP12 infection still
occurred, albeit at significantly reduced levels. Whether residual
infection levels under these conditions reflect incomplete blockade of
t h eg e n et a r g e t so rt h ep r e s e n c eo fa l t e r n a t i v ee n t r yp a t h w a y si sn o t
clear. However, the fact that RVFV MP12 infection across disparate
hosts, including insects and mammals, was significantly reduced by
both genetic and pharmacological inhibitors of macropinocytosis and
PKC suggests that this is a general requirement for efficient RVFV
infection. Furthermore, it implicates PKCe as playing a specific and
important role in this process. Importantly, PKCe is dispensable in
mice [40], suggesting that this cellular factor may be a suitable target
for non-toxic anti-RVFV therapeutics.
By screening a library of known biologically active drugs, this
study provides insight into a number of aspects of RVFV infection.
First, this strategy allowed us to identify previously unknown
inhibitors of the MP12 strain of RVFV. While this is an attenuated
strain, it is likely that many of the inhibitors we found will also
block infection of wild type RVFV [41,42]. This alone is an
essential starting point to develop more potent therapeutics and
creates new biological probes. Second, we found that many of the
same cellular pathways that are required for infection in the
mammalian host are also required for infection in an insect host.
Lastly, by extending our approach to additional medically relevant
arthropod-borne viruses for which there are no current therapeu-
tics, we may be able to identify additional inhibitors and targets as
a first step toward the control of these pathogens.
Materials and Methods
Cells, viruses, antibodies, and reagents
Drosophila S2 cells were grown and maintained in Schneiders
Drosophila media supplemented with 10% FBS (JRH), 100 mg/mL
penicillin/streptomycin and 2 mM L-glutamine. Mammalian cells
were maintained in DMEM supplemented with 10% FBS
(GIBCO) 100 mg/mL penicillin/streptomycin and 2 mM L-
glutamine. Vero-E6, 293T/17 and H358 cells are available from
ATCC. RVFV strain MP12 was grown in Vero-E6 cells
supplemented with 10% FBS (GIBCO). MP12 used to infect
Drosophila cells was concentrated through a Centricon-70
+
30,000 kDa filter. Poliovirus strain Sabin 2 was a kind gift from
C. Coyne (U. Pitt) grown and purified as described [43].
Drosophila C virus was grown and purified as described [44].
Mouse monoclonal antibodies to RVFV N (1D8-1-2), GN (7B6-2-
2-2) and GC (R2-1F7-3-2) were a gift from C. Schmaljohn
(USAMRIID), and rabbit polyclonal antibody to RVFV GN (154)
(PROSCI) were used to detect RVFV antigens. Anti-TGN46
(Abcam) and Anti-GM130 (Abcam) were used to detect the Golgi
apparatus in mammalian and Drosophila cells respectively. Mouse
anti-enterovirus VP1 (Ncl-Entero) was used to detect poliovirus.
Anti-DCV [44] was used to detect Drosophila C virus.
Fluorescently labeled secondary antibodies were obtained from
Jackson Immunochemicals or Molecular Probes. The PKC
inhibitor set was obtained from (Calbiochem), the LOPAC1280
library and all other inhibitors were purchased from Sigma.
Infections and Immunofluorescence
Cells were infected with the indicated MOI of virus in complete
media and fixed and processed for immunofluorescence at the
indicated time point post infection. For RVFV MP12 infections,
cells were fixed in PBS 4% formaldehyde, washed twice in PBS
0.1% TritonX-100 (PBS-T), and blocked in PBS-T/2% BSA.
Primary antibodies were diluted in block, added to cells, and
incubated overnight at 4uC. Cells were washed in PBS-T, and
incubated in secondary antibody for over one hour at room
temperature. Alternatively, FITC conjugated anti-RVFV N was
incubated overnight at 4uC. For poliovirus infections, cells were
fixed with ice-cold methanol for 5 min followed by permeabiliza-
tion with 0.1% Triton X-100 in PBS. Cells were incubated with
anti-VP1 for 1 h at RT. Cells were counterstained with Hoescht
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microscope (ImageXpress Micro), and quantification was per-
formed using MetaXpress image analysis software.
Small Molecule Screen
Each compound in the library was added at 10mM per well 1 day
after seeding cells in 384 well plates. Mammalian cells were seeded
at 6,000 cells 24 hours prior to drug treatment, and infected with
RVFV MP12 at MOI=0.08 for 16 hours, for an average infection
of 6%. Drosophila cells were seeded at 20,000 cells per well 24 hours
prior to drug treatment, and infected with RVFV MP12 at
MOI=0.02 for 48 hours, for an average infection of 15%. The
293T/17 cells were fixed and stained with FITC conjugated anti-
RVFV N and counter-stained with DAPI. The Drosophila cells were
fixed and stained with purified anti-RVFV GN followed by anti-
mouse texas red secondary. Next, the cells were stained with FITC
conjugated anti-RVFV N and counter-stained with DAPI.
Screen Analysis
Three sites in each well for each wavelength were imaged at 106
for mammalian cells and 206for Drosophila cells using automated
microscopy (ImageXpressMicro). Automated image analysis was
used to calculate the number of Dapi
+ cells and the number of
infected cells (FITC
+, Texas Red
+). These metrics were used to
calculate the percent infection for each site, which was averaged for
each well. Percent infection was log-transformed, and the median
and interquartile range were used to calculate a robust Z score:
(log10(%infection)-log10(median))/(IQR*0.74) [24]. Outliers were
identified if the Z score was ,21.7 in both replicates (p,0.002).
Drug validation and IC50s
Mammalian 293T/17 cells were seeded at 25,000 cells per well
and Drosophila S2 cells were seeded at 100,000 cells per well in 96
well plates. Drugs were added at 10 mM concentrations for initial
validation or as a dilution series for IC50 assays for 30 minutes
before infection. 293T/17 cells were infected for 12–15 hours at
an MOI=0.3 for an average infection of 20%, and S2 cells were
infected at an MOI=0.05 for 36 hours, for an average infection of
10%. Cells were fixed, stained and imaged as described above.
IC50 values were calculated using percent infection normalized to
no drug controls and set at 100%. Sigmoidal curve fit equations in
GraphPad Prism are shown. The IC50 values are the average of at
least two experiments.
Time-of-addition
Mammalian 293T/17 cells were seeded at 18,000 cells per well
in 96 well plates 48 hours prior to infection. Drugs were added at
indicated concentrations 30 minutes prior to infection for pre-
treatment samples. Virus was added at an MOI=0.3 for 1 hour
for an average infection of 20%, cells were washed to remove
unbound virus, and media was replaced containing drugs in both
pre-infection treatment and post-infection treatment conditions.
Cells were infected for 12–15 hours, then fixed and processed for
immunofluoresence as above. Percent infection was calculated;
infected cells with no inhibitor were set to 100% and used to
normalize the treated samples for three independent experiments.
Mammalian RNAi
6,000 293T cells were reverse transfected with 20nM siRNA
using HiPerfect according to the manufacturers protocol (Qiagen).
48 hours post-transfection, cells were infected with RVFV MP12
(MOI=1) for 12 hours. 293T cells were infected with poliovirus at
an MOI=1 for 8 hours. H358 cells were infected with RVFV
MP12 for plaque assays or poliovirus at an MOI=10 for 8 hours
for immunofluorescence. siRNAs were purchased from Dharma-
con (NonTargeting, PKCe, PKCd). Hairpin constructs were
generated against a control (Dharmacon NTS_C) or PKCepsilon
(Dharmacon#849) and were transfected into H358 cells. Puro-
mycin selection resulted in stable cell lines that express the
hairpins. Plaque assays were performed on BHK or Vero cells and
fixed at three days post infection.
Fly strains and infections
Flies were grown on standard cornmeal dextrose medium
supplemented with dry yeast at room temperature. The following
fly strains were used in this study: w1118, Actin-Gal4, Heat shock-
Gal4, UAS-PKCi (Bloomington), UAS-PKC98E IR (VDRC).
Adult flies of the indicated genotypes were injected with ,50 nL
and monitored daily for lethality or were collected for immunoblot
analysis or viral titers performed as above [44].
Immunoblot analysis
Cells or 4–6 pooled flies were lysed in radioimmunoprecipita-
tion (RIPA) buffer supplemented with a protease inhibitor cocktail
(Boehringer). Samples were separated by non-reducing SDS-
PAGE for anti-RVFV antibodies, and reducing SDS-PAGE for
other antibodies. RVFV antigens were detected with a combina-
tion of purified anti- RVFV GN and GC. PKCe was detected with
anti-PKCe (Santa Cruz). HRP-conjugated secondary antibodies
(Jackson Biochemical) and FEMTO SuperSignal Chemilumines-
cence Reagent were used for visualization.
Supporting Information
Figure S1 Drug toxicity can be determined by quanti-
tation of cell number. Robust Z scores for the nuclei counts in
duplicate are plotted for each of the four plates of the LOPAC
screen. Each plate is shown with a different symbol. Drugs with a
Z,22.0 in duplicate are considered cytotoxic. A. Mammalian
293T cells. B. Drosophila S2 cells.
(TIF)
Figure S2 PKC98E is depleted by RNAi in vivo. Semi-
quantitative RT-PCR was performed on total RNA purified by
Trizol (Invitrogen) from either control (+.UAS-PKCe IR) or
depleted (Actin-Gal4.UAS-PKCe IR) flies using primers either
against PKCe or control (clathrin heavy chain).
(TIF)
Table S1 Screen Results for inhibitors of RVFV infection.
(XLSX)
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